Breakthroughs in molecular medication have positioned the amyloid-? (A?) pathway at the center of Alzheimer’s ailment (AD) pathophysiology. Even though the in-depth molecular mechanisms in the pathway as well as the spatial-temporal dynamics bringing about synaptic failure, neurodegeneration, and medical onset remain under intense investigation,